QT prolongation risk factors and a monitoring strategy in rifampicin-resistant tuberculosis: Findings from the STREAM Stage 2 trial
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Treatment of rifampicin-resistant tuberculosis (RR-TB) involves drugs that can prolong the QT interval. There is limited data on risk factors and the level of cardiac monitoring required. We analysed STREAM Stage 2 data to address these issues.
Methods
A post-hoc analysis was undertaken of data from participants allocated to 3 regimens: 9-month control (n=202), 9-month oral (n=211) and 6-month (n=143). Risk factors for development of a QT or QTcF interval ≥500ms were assessed. The diagnostic accuracy of a monitoring strategy for QT/QTcF prolongation was tested.
Results
QT/QTcF ≥500ms occurred on all regimens: 9-month control (n=14 (6.9%)), 9-month oral (n=8 (3.8%)) and 6-month (n=6 (4.2%)).
The participating country with the highest number of QT/QTcF interval ≥500ms events was Mongolia (18 events [64%]). A higher baseline QTcF was significantly associated with development of QT/QTcF ≥500ms (OR 1.05; 95% CI 1.03 to 1.07, p<0.001). There was a suggested association between moxifloxacin (compared to levofloxacin, OR 2.49; 95% CI 0.92 to 6.71, p = 0.07) and a higher baseline TSH (OR 3.52; 95% CI 0.84 to 14.73, p=0.08) and increased odds of QT/QTcF ≥500ms.
The monitoring strategy performed well in the control (sensitivity 100%; specificity 62%; positive predictive value (PPV) 13% and negative predictive value (NPV) 100%) and oral (sensitivity 100%, specificity 59%, PPV 6% and NPV 100%) regimen groups.
Conclusions
Baseline QTcF and country were associated with increased odds of QT/QTcF prolongation. The monitoring strategy performed well in the identification of participants at higher risk of QT/QTcF prolongation.
